Results for tag: "Male Hypogonadism Drug"

Male Hypogonadism is a condition in which the body does not produce enough testosterone, the primary male sex hormone. It is a type of endocrine and metabolic disorder, and is typically treated with drugs. These drugs are designed to replace the missing testosterone, and can be administered orally, intramuscularly, or topically. Common side effects of these drugs include acne, hair loss, and increased risk of prostate cancer. The Male Hypogonadism Drug market is a subset of the larger Endocrine and Metabolic Disorders Drugs market. It is composed of a variety of drugs, including testosterone replacement therapies, selective estrogen receptor modulators, and aromatase inhibitors. These drugs are used to treat a range of conditions, including hypogonadism, delayed puberty, and infertility. Some companies in the Male Hypogonadism Drug market include AbbVie, Eli Lilly, Pfizer, and Teva Pharmaceuticals. These companies produce a variety of drugs to treat male hypogonadism, including testosterone replacement therapies, selective estrogen receptor modulators, and aromatase inhibitors. Show Less Read more